Cypherpunk Technologies reported a net loss of $37.8 million for the first half of 2026. The Nasdaq-listed company announced it will shift its primary focus to advancing its cancer drug candidate, Sirexatamab, through a potential spin-out or partnership.
This strategic pivot follows a Phase 2 clinical trial where the drug failed to outperform the control group in progression-free survival. With only $7.6 million in cash reserves and a stock valuation trading below the value of its crypto holdings, the company faces pressure to secure new funding for future regulatory steps.
Key facts
- Cypherpunk holds approximately 323,394 ZEC, valued at roughly $157 million, with Gemini serving as the custodian.
- The company’s enterprise value trades at a multiple of 0.47x to 0.96x relative to its net asset value.
- Cash equivalents stood at $7.6 million as of June 30, 2026, raising concerns about liquidity for upcoming trials.
- The FDA granted Fast Track designation to Sirexatamab in May 2026, despite the recent Phase 2 setback.
- Management has not yet finalized whether to pursue a spin-out or a partnership to fund further development.
Why it matters
The divergence between Cypherpunk’s market capitalization and its substantial Zcash reserves highlights investor skepticism about its dual business model. The pivot to biotechnology requires significant capital, which the company currently lacks, forcing it to rely on external financing or structural changes like a spin-out. This situation underscores the risks for hybrid companies that hold volatile crypto assets while pursuing capital-intensive traditional industries like pharmaceuticals.